BCAX

Bicara is a December-2018 clinical-stage biopharma whose entire future, by its own words, is "highly dependent on the success of ficerafusp alfa." There is no revenue (none in FY2023, FY2024, or FY2025), no approved product, and the 10-K is explicit that the company "will continue to incur significant financial losses for the foreseeable future" and expects them to "increase" as it advances clinical development. Net loss widened to -$138M in FY2025 from -$68M in FY2024 and -$52M in FY2023 — a doubling year-over-year — with operating cash flow of -$107M. ROE of -34.4% is a mechanical artifact of burning equity, not a profitability signal. This is a binary, single-catalyst story: ficerafusp alfa either reads out and approves, or the equity is worth a fraction of today's price. That is the "unknowable risk" bucket, and none of the data here lets a fundamentals-or-valuation analyst underwrite it.

The one genuine positive is the balance sheet. Liabilities are just $29.5M against $401M of stockholders' equity (0.07x liabilities/equity), and current assets of $422M dwarf $28.9M of current liabilities. Note that headline cash fell 80.3% to $96.7M, but the gap to $422M of current assets is almost certainly short-term investments/marketable securities — so liquidity is intact, not impaired. Against ~$107M annual operating burn, that implies roughly three years of runway before another raise. But runway is not value: shares outstanding already grew 20.1% to 65.5M in a single year, and the filing flags that if the company "is unable to raise capital when needed, or on acceptable terms" it may not complete development — i.e., expect further dilution.